Streja Dan
Section of Endocrinology, Veterans Affairs Medical Center of West Los Angeles, West Hills, California 91307, USA.
Endocr Pract. 2005 Mar-Apr;11(2):83-90. doi: 10.4158/EP.11.2.83.
To establish criteria defining hypoglycemia as detected by the continuous glucose monitoring system (CGMS) in patients with type 1 diabetes that best predict hypoglycemia unawareness (HUN), established by a validated questionnaire.
Adult patients were selected for inclusion in this study if they had long-standing type 1 diabetes, a fasting level of C peptide of < or = 0.6 ng/mL, commitment to achieving glycemic control, and a hemoglobin A1c value no higher than 9%. After clinical data and self-monitoring of plasma glucose data were collected, patients underwent a 72-hour glucose monitoring session with use of a Medtronic-MiniMed CGMS. The presence of HUN was determined by a questionnaire. Factors independently associated with HUN were estimated by multivariate independent analysis.
Our study group consisted of 60 patients (33 women and 27 men) who ranged in age from 18 to 84 years (mean, 50.4) and had had diabetes for 5 to 56 years (mean, 23.8). The best predictor of HUN was the maximal duration of hypoglycemia, as determined by the CGMS (P = 0.001). Detection of hypoglycemic episodes with a duration of more than 90 minutes identified patients who had HUN with an 88% specificity and 75% sensitivity. HUN was also significantly associated with use of angiotensin-converting enzyme inhibitors or angiotensin receptor blockers (P = 0.003) and with a longer duration of diabetes (P = 0.008).
The CGMS can be used for objective detection of patients with HUN.
建立1型糖尿病患者连续血糖监测系统(CGMS)检测低血糖的标准,该标准能最佳预测通过有效问卷确定的低血糖无意识(HUN)情况。
入选本研究的成年患者需满足长期1型糖尿病、空腹C肽水平≤0.6 ng/mL、致力于实现血糖控制且糖化血红蛋白值不高于9%。收集临床数据和自我监测的血浆葡萄糖数据后,患者使用美敦力MiniMed CGMS进行72小时血糖监测。通过问卷确定HUN的存在。通过多变量独立分析评估与HUN独立相关的因素。
我们的研究组由60名患者组成(33名女性和27名男性),年龄在18至84岁之间(平均50.4岁),糖尿病病程为5至56年(平均23.8年)。CGMS确定的低血糖最大持续时间是HUN的最佳预测指标(P = 0.001)。检测到持续时间超过90分钟的低血糖发作可识别出HUN患者,特异性为88%,敏感性为75%。HUN还与使用血管紧张素转换酶抑制剂或血管紧张素受体阻滞剂显著相关(P = 0.003),且与糖尿病病程较长有关(P = 0.008)。
CGMS可用于客观检测HUN患者。